Highline Capital Management’s NovoCure NVCR Stock Holding History

Highline Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-774,910	Closed	-$24.3M	–	41
2018 Q2	$24.3M	Sell	774,910 -255,000	-25%	-$7.09M	0.81%	33
2018 Q1	$22.5M	Sell	1,029,910 -444,700	-30%	-$9.56M	0.77%	29
2017 Q4	$29.8M	Sell	1,474,610 -39,400	-3%	-$759K	0.99%	28
2017 Q3	$30.1M	Sell	1,514,010 -221,800	-13%	-$4.36M	0.85%	31
2017 Q2	$30M	Sell	1,735,810 -59,900	-3%	-$773K	0.95%	29
2017 Q1	$14.5M	Sell	1,795,710 -22,369	-1%	-$162K	0.42%	37
2016 Q4	$14.3M	Hold	1,818,079	–	–	0.41%	33
2016 Q3	$15.5M	Buy	1,818,079 +62,200	+4%	+$567K	0.53%	35
2016 Q2	$20.5M	Buy	1,755,879 +222,200	+14%	+$2.78M	0.78%	29
2016 Q1	$22.2M	Buy	1,533,679 +109,639	+8%	+$1.57M	0.94%	28
2015 Q4	$30.3M	Buy	+1,424,040	New	+$34M	1.43%	23

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Highline Capital Management's NVCR Position: Q3 2018 in Review

Highline Capital Management sold out of NovoCure (NVCR) in Q3 2018, closing a stake of 774,910 shares — an estimated $24.3M sold.

Highline Capital Management first reported a position in NVCR in Q4 2015 and held it in 11 quarters. The position peaked at $30.3M in Q4 2015. 176 funds tracked by Wall St. Rank hold NVCR as of Q3 2018.

Highline Capital Management reported no remaining NovoCure position as of Q3 2018 after selling out during the quarter.
Highline Capital Management sold 774,910 NovoCure shares in Q3 2018, an estimated $24.3M.
Highline Capital Management first reported a position in NovoCure in Q4 2015 and held it in 11 quarters.
Highline Capital Management's NovoCure position peaked at $30.3M in Q4 2015.
176 funds tracked by Wall St. Rank held NovoCure as of Q3 2018.

Based on Highline Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.